Prognostic value of serum CYFRA21‐1 and CEA for non‐small‐cell lung cancer

Cancer Medicine

Zhi-Hui Zhang¹  Yun-Wei Han³  Hui Liang² 

[1] Department of Thoracic Surgery, Affiliated Hospital of Tai'an Medical University, Tai'an, Shandong, China;Department of Medical Imaging, The General Hospital of Jinan Military Command, Jinan, Shandong, China;Department of Oncology, The First Affiliated Hospital of Sichuan Medical University, Luzhou, Sichuan, China

关键词: Cancer;    carcinoembryonic antigen;    keratins;    meta‐analysis;    non‐small‐cell lung cancer;    prognosis;   

DOI  :  10.1002/cam4.493

来源: Wiley

【 摘 要 】

Abstract

The aim of the study was to assess the clinical prognostic value of serum cytokeratin 19 fragment (CYFRA21-1) and carcinoembryonic antigen (CEA) for non-small-cell lung cancer (NSCLC) patients. Literatures related to effects of serum CYFRA21-1 and CEA on the prognosis of lung cancer patients were retrieved from databases such as PubMed, Springer Link, Embase, Wanfang, and CNKI. Meta-analysis was carried out using RevMan 5.1 software. Ten literatures involving 1990 NSCLC patients were selected in this study. Total survive estimation merging hazard ratio (HR) in all NSCLC patients with high-level serum CYFRA21-1 was 1.64 (95% CI 1.46–1.84, P < 0.001) and that in all NSCLC patients with high level serum CEA was 1.46 (95% CI 1.28–1.65, P < 0.001). Serum CYFRA21-1 and CEA can be used as prognostic factors of NSCLC patients. Combinative detection of the two indices will be more reliable.

【 授权许可】

CC BY   
© 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.